TrialReach launches new platform giving patients greater access to clinical trials
Friday, September 20, 2013
TrialReach, a London-based web site that connects patients to clinical trials worldwide, has launched a new platform that dramatically reduces the time and costs required to find clinical trial participants.
One of the biggest challenges in clinical research is finding patients. It is estimated that 80% of all trials miss their deadlines, causing losses of up to $8 million per drug per day and slowing the process of getting new treatments to patients. The challenge is even greater for smaller independent medical research teams who have limited resources to promote their trials and find the patients they need.
TrialReach’s new platform offers a much needed solution to these problems. To make the process simple for patients, complicated medical research protocols are converted into simple, patient-friendly interactive multimedia web pages. The information is easy to understand, free of medical jargon and includes maps and pictures. Patients can find out immediately if they are eligible for a trial through easy-to-use pre-screeners.
Medical researchers now can reach millions of patients in just a few clicks. The TrialReach platform is open and virtually free to all research teams, even to smaller biotech firms and academic institutions.
“TrialReach is helping us to solve one of the biggest challenges in medical research—making it much easier for patients to find us, learn more and then volunteer to be in our clinical trials,” said professor Steve Williams of King’s College London.
The new TrialReach platform was developed over the last three years with extensive input from patients and medical research teams worldwide and is now available for use by any research team.
“The new TrialReach platform is a win-win for patients and clinical researchers,” said TrialReach CEO Pablo Graiver. “Our goal is to democratize the information and access to medical research, so it can transform the whole industry and not just selected companies.”